Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Cost-Related Motivations for Conducting Research

Cost-Related Motivations for Conducting Research Opinion VIEWPOINT Participants Should Be Informed Many groups in the United States are concerned about after ranibizumab received approval from the US Food Rahul K. Nayak, BSE Clinical Center, the increasing cost of health services and have sought and Drug Administration specifically to treat age- Department of to reduce health care spending while maintaining the related macular degeneration, off-label bevacizumab re- Bioethics, National quality of care. A promising approach to this goal is to mained the most popular treatment choice because ra- Institutes of Health, conduct more head-to-head clinical trials that compare nibizumab was significantly more expensive: Bethesda, Maryland. the effectiveness of less expensive treatment options ranibizumab costs nearly 40 times more than Steven D. Pearson, with that of more costly treatments. However, this type bevacizumab. Nevertheless, many physicians began MD, MSc of research raises questions about how the purposes of using the more expensive ranibizumab, which was es- Clinical Center, the studies are presented to potential research partici- timated to cost Medicare an additional $1.1 billion over Department of pants. a 2-year period between 2008 and 2009. Bioethics, National Institutes of Health, Should research participants be informed if widely Was inexpensive, off-label bevacizumab as safe and Bethesda, Maryland, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Cost-Related Motivations for Conducting Research

JAMA , Volume 311 (15) – Apr 16, 2014

Loading next page...
 
/lp/american-medical-association/cost-related-motivations-for-conducting-research-ayCt3r5b6J
Publisher
American Medical Association
Copyright
Copyright 2014 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2014.1821
pmid
24615527
Publisher site
See Article on Publisher Site

Abstract

Opinion VIEWPOINT Participants Should Be Informed Many groups in the United States are concerned about after ranibizumab received approval from the US Food Rahul K. Nayak, BSE Clinical Center, the increasing cost of health services and have sought and Drug Administration specifically to treat age- Department of to reduce health care spending while maintaining the related macular degeneration, off-label bevacizumab re- Bioethics, National quality of care. A promising approach to this goal is to mained the most popular treatment choice because ra- Institutes of Health, conduct more head-to-head clinical trials that compare nibizumab was significantly more expensive: Bethesda, Maryland. the effectiveness of less expensive treatment options ranibizumab costs nearly 40 times more than Steven D. Pearson, with that of more costly treatments. However, this type bevacizumab. Nevertheless, many physicians began MD, MSc of research raises questions about how the purposes of using the more expensive ranibizumab, which was es- Clinical Center, the studies are presented to potential research partici- timated to cost Medicare an additional $1.1 billion over Department of pants. a 2-year period between 2008 and 2009. Bioethics, National Institutes of Health, Should research participants be informed if widely Was inexpensive, off-label bevacizumab as safe and Bethesda, Maryland,

Journal

JAMAAmerican Medical Association

Published: Apr 16, 2014

References